ReviewJournal of inflammation research2026
Research Progress on Traditional Chinese Medicine Preparations in Respiratory Inflammatory Diseases.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global burden of respiratory inflammatory diseases, such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD), continues to rise, highlighting the urgent need for safer and more effective therapeutic strategies. Conventional treatments provide symptomatic relief but remain limited by adverse effects, tolerance, and incomplete resolution of inflammation. In recent years, traditional Chinese medicine (TCM) formulations have gained growing attention as promising complementary or alternative approaches due to their holistic and multi-targeted pharmacological actions. This review summarizes current preclinical and clinical evidence on the application of classical TCM preparations-including Xuebijing, Qingkailing, Xiyanping, Tanreqing, Chuankezhi, Shuanghuanglian, and Yejuhua injections-in the management of respiratory inflammatory diseases. These herbal treatments exhibit significant anti-inflammatory, antioxidative, and immunomodulatory effects through modulation of key signaling pathways such as NF-κB, MAPK, and TLRs. Importantly, clinical studies suggest that these TCM preparations can alleviate respiratory symptoms, reduce disease exacerbations, and enhance patient quality of life, highlighting their potential clinical significance and translational value in managing respiratory inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.